We focus on discovering undetected relationships between drugs with a known safety profile and diseases to identify new indications. We do this by utilizing Hyper-C, our artificial intelligence powered platform that allows us to detect these relationships with unprecedented speed.
Hyper-C is operated by our team of highly skilled computational biologists that carefully analyze the data to produce unique insights and opportunities.
The results are new therapy options that find their way to patients faster, more cost-effectively, and more efficiently than ever before.
Hyper-C stands for Hyper Connectivity. It’s our proprietary AI platform housing an enormous collection of algorithmic intelligence.
The platform feeds on big data and uses its algorithms and data integration to build molecular models which go through an iterative refinement process matching them to diseases. This sophisticated process utilizing thousands of pre-computed models effectively matches compounds to diseases for more efficient biological testing and clinical trials.
Hyper-C is unique in that unlike other AI platforms, it eliminates the black box problem. Its results provide a clear mechanism of action hypothesis that aids in regulatory requirements.
Delta4 is a biotech company focused on discovering new indications for existing drugs with known safety profiles.
We accelerate new treatment options to improve the health of patients and get them into their hands faster, more safely, and more efficiently than the traditional approach.
The scientific aim of PerMediK is to support the development of a path towards personalized medicine in chronic kidney disease …
Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical stage biotechnology company, and Delta4, an Austrian …
Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological and …